Search Weight Loss Topics:

Page 20«..10..19202122..3040..»

Home » Testosterone » Page 20

We love the things that help get us through hard times with a love that surpasseth understanding. With that in mind, I think you will understand when I say that this remake of All Creatures Great and Small is among the greatest things bestowed upon humankind in this last year. It is a gentle human drama filled with well-intentioned gentle humans trying their best, and the few times they are not trying their best, they are gently ashamed. I go into every new episode with the relief of I am about to watch a very nice thing. In these times, the appeal of that cannot be overestimated.

This entire episode revolves around a Pekingese. Yes, correct, it is the extremely wealthy Mrs. Pumphreys dog Tricki Woo, a dog I could not possibly love more, played by Derek. Wonderful dog acting from Derek once again this episode. Tricki is a pile of fluff. A Tribble of a dog. What is the greatest thing about Tricki? Is it his absurd leonine mane? The giant cushions he sleeps on? The fact that he shakes paws (I LITERALLY screamed when this happened)? His little snuffling noises? That Mrs. Pumphrey calls him my boofums? OR E, ALL OF THE ABOVE.

But before we get to Tricki, we also have Tristan. Or Tris, as I am forever calling him after last episode. Tris spends the episode asking Siegfried for money so he can go back to school and, presumably, have more fun than answering the phone at the practice and mixing horse medicine. Siegfried is understandably reticent because Tris keeps failing his exams, so Tris must prove himself. This somehow comes down to taking Tricki on walks, making the latter am I going to say it, yes I am a perambulating Pekingese (we have fun here). The practice has possession of Tricki because he is dangerously overweight. When asked if Mrs. Pumphrey has been sticking to his diet of dry dog biscuits, she says yes, to the letter, and then charmingly adds, perhaps not every letter. I AM STEALING THIS, DIANA RIGG. (RIP.)

She has been feeding Tricki calfs foot jelly, cod liver oil, Beef Wellington, and a bowl of Horlicks. If you are, like I am, an American, you might have said is that like ice cream? Nope! Think about milk, but its hot and also you add malt to it. I know, I dont get it either. Its slogan in 1961 was Horlicks the food drink of the night. NOPE. It was actually created in the United States and brought on expeditions to the North and South Pole, and then eventually that trickled on down to it being fed to the overly pampered Pekingese set.

James is concerned enough about Tricki that he takes him to stay at the practice so they can feed him appropriately and take him on walks. My notes for his visit at Mrs. Pumphreys just say GIMME THAT DOG, but we now need to move onto the very important fact that Tricki has a tiny, dog-size chaise longue. Has anyone made a website for Extravagant Pet Furniture, because I will look at that site every single day.

The drama of the episode hinges around the Hamper o Snacks, which Tris and Siegfried spend the following days pilfering. Despite Tris taking Tricki on very long walks and feeding him the presumably joyless dry dog food he must now consume for his health, Tricki is gaining rather than losing weight. This is because Siegfried left the hamper open and Tricki has been merrily dragging whole slices of ham out of it with his tiny dog strength. There is a big TO-DO about this, but! Lets talk about Clive real quick.

Dyou remember Clive? The massive bull who looks like one of those 18th-century paintings where you think that cows proportions are off, but really we just arent used to breeds of cow that arent Holsteins? Clive belongs to Helen and he has been sired out, i.e. hired to do it with someone elses cows, but hes not doing it, so James has to give him a shot of testosterone.

This is an unremarkable plot point, because the testosterone, undramatically, works, but its there to (1) let us once again see Clive, who is truly amazing and I love him, (2) show us everyone wearing velvet pants, or what I think are velvet pants, and it makes me want velvet pants, and (3) get James to give Helen a lift home, until they run into Hot Neville, who seems to have forgiven James for killing his horse. James has a Jessies Girl moment as he looks at the two flirting, but this dynamic remains the least interesting to me, because we know James and Helen are probably going to get married. Its very, yes, yes, check this off the list, now lets look at the others.

The relationships that are of true import here are Siegfried/Mrs. Hall and Mrs. Pumphrey/Tricki Woo. I cant nail down Siegfried and Mrs. Halls situation, and it makes me love it all the more. He knows more about her and her difficulties with her son than were allowed to know. He clearly feels something more for her, but its under enough layers of subtext that it seems hes not allowed to properly express it. They have this unspoken arrangement in their dynamic that I am all about and it feels like the actors have sat down and had a good discussion about their backstory and ITS JUST SO GOOD. As for Mrs. Pumphrey and Tricki Woo, that is a love for the ages.

Will we ever find out Whats Up With Edward?

Do velvet pants wear well?

When Helen inevitably dumps Hot Neville, will he find solace in the world of botany?

Will I descend into the uttermost depths of the All Creatures fandom, and now that weve found out the practices telephone number, change my WiFi Network to Darrowby2297?

Keep up with all the drama of your favorite shows!

Read the original here:
All Creatures Great and Small Recap: The One With the Snack Hamper - Vulture

Fatigue is one of the most common adverse events of systemic therapy in patients with metastatic renal cell carcinoma (RCC). The aim of multicenter randomized phase 2 study was to determine the efficacy and safety of testosterone in patients with fatigue developed during targeted therapy.

Male patients with metastatic clear-cell RCC, normal prostate-specific antigen level, low testosterone level, and no evidence of hypothyroidism receiving first-line sunitinib or pazopanib with fatigue were randomly assigned (1:1) to either testosterone undecanoate (1000mg) and targeted therapy or targeted therapy alone. The primary endpoint was the mean change of fatigue from baseline to 28 days according to the Functional Assessment of Chronic Illness Therapy-Fatigue scale. Secondary endpoints were safety, Functional Assessment of Cancer Therapy-Kidney Symptom Index 19, testosterone serum concentrations, red blood cell count, and hemoglobin level.

Sixty patients were assigned to receive testosterone and targeted therapy (N=30) or targeted therapy alone (N=30). As of the data cutoff on December 30, 2019, median follow-up was 18.2 months. The study achieved its primary endpoint based on the significant differences at day 28 favoring testosterone over targeted therapy alone regarding the decreased level of fatigue (difference between groups, 22.5 points; 95% confidence interval, 18.4-26.6; P=0.012). Significant changes in scores demonstrating the enhanced quality of life with testosterone compared with targeted therapy were also observed for Functional Assessment of Cancer Therapy-Kidney Symptom Index 19 disease-related symptoms (P=0.01). There were nonsignificant differences in red blood cell count and hemoglobin level between the 2 groups (all P>0.05).

Male patients with metastatic RCC and hypogonadism receiving testosterone had less fatigue and better symptom control during targeted therapy.

American journal of clinical oncology. 2021 Jan 27 [Epub ahead of print]

Ilya Tsimafeyeu, Yulia Tishova, Ruslan Zukov, Pavel Borisov, Anastasia Bondarenko, Kristina Zakurdaeva

Kidney Cancer Research Bureau Institute of Oncology, Hadassah Medical Moscow RUDN University I.M. Sechenov First Moscow State Medical University RakFond, Moscow V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk City Clinical Oncology Center, St. Petersburg, Russia.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/33512910

More here:
Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Pha... - UroToday

Luna Liu,1,2 Shuang Liu,1,2 Qianmei Song,1,2 Dandan Luo,1,2 Yu Su,1,2 Xiangyu Qi,1,2 Qian Wang,3 Jing Ning,1,2 Youyuan Lv,1,2 Qingbo Guan1,2,4

1Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250021, Peoples Republic of China; 2Shandong Provincial Key Laboratory of Endocrinology and Lipid Metabolism, Institute of Endocrinology and Metabolism, Shandong Academy of Clinical Medicine, Jinan, Shandong 250021, Peoples Republic of China; 3Department of Ultrasound, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, Peoples Republic of China; 4Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, Peoples Republic of China

Correspondence: Qingbo Guan Tel +86-531-68776375Fax +86-531-87068707Email doctorguanqingbo@163.com

Objective: Obesity and metabolic syndrome have been reported to exert an impact on the male reproductive system with decreasing levels of serum total testosterone (TT); however, the effect of different metabolic obesity phenotypes on testosterone has been poorly studied. We aimed to evaluate the association of metabolic obesity phenotypes and total testosterone levels in a Chinese male population.Methods: We performed a retrospective study based on an epidemiological investigation, a total of 4,081 male individuals aged from 40 75 years old were recruited. The population was classified as metabolically healthy normal weight (MHNW), metabolically healthy overweight/obese (MHO), metabolically unhealthy normal weight (MUNW), and metabolically unhealthy overweight/obese (MUO) according to normal weight (BMI< 25.0) and overweight/obesity (BMI 25.0) with or without metabolic syndrome.Results: We collected 563 hypotestosteronemia among 4,081 male individuals. The odds ratios (ORs) (95% CIs) of hypotestosteronemia in obesity and metabolic syndrome were 3.072 (2.414 3.911) and 3.294 (2.631 4.125), respectively, after adjusting for age, luteinizing hormone, smoking status, and alcohol consumption. Compared to the MHNW group, male subjects in MHO, MUNW, and MUO groups had decreased serum TT levels. Additionally, the MUO group had a lowest concentration of serum TT and a highest proportion of hypotestosteronemia. There was no significant difference of TT levels between the MHO and MUNW groups.Conclusion: Obesity and metabolic syndrome are independent risk factors of hypotestosteronemia in Chinese male populations. Our study also suggested that individuals with MHO, MUNW, and MUO have a higher risk of developing hypotestosteronemia.

Keywords: metabolic obesity phenotypes, testosterone, metabolically healthy overweight/obese, metabolically unhealthy normal weight, hypotestosteronemia

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the rest here:
Association of Metabolic Obesity Phenotypes and Total Testosterone in | DMSO - Dove Medical Press

RALEIGH, N.C., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a specialty pharmaceutical company focusing on treating conditions that are primarily associated with testosterone deficiency, today announced that it has appointed Himanshu H. Shah and Shalin Shah as co-CEOs to drive the next phase of growth as the company looks to a potential launch of KYZATREX in Q4 2021 and further the development of Marius deep clinical pipeline.

Himanshu H. Shah brings over 30 years of experience across global capital markets and will continue his role as chairman of the board in addition to co-CEO. He has advised numerous public and private companies over the past decades to help them unlock substantial shareholder value and execute both innovative and pragmatic business strategies.

I am proud to continue serving Marius and work on developing the best treatment options for men with hypogonadism, a common but not widely discussed disease among patients and prescribers, said Himanshu H. Shah, chairman and co-CEO of Marius Pharmaceuticals. Misconceptions about hypogonadism are having a huge impact on the health of millions of men globally and costing the U.S. healthcare system alone billions of dollars annually. There is a huge opportunity for Marius to address these issues and drastically alter the testosterone therapy landscape.

Shalin Shah will also step into the role of co-CEO from chief financial officer and executive vice president of strategy for Marius. Shalin has been integral in driving overall strategy at Marius for the past four years and will oversee the growth of the team and execution of innovative models as it expands both clinically and commercially to become a leading pharmaceutical company.

I am excited for the opportunity to serve Marius in this new capacity, especially at a time when the world is seeing technology and healthcare intersect more than ever, truly helping patients, said Shalin Shah, co-CEO of Marius Pharmaceuticals. I am confident in Marius mission to better the lives of patients by ensuring adequate levels of testosterone and enhance patient care through disruptive technologies and personalization.

Om Dhingra, Ph.D., led the company from initial development of the lead compound through two successful Phase 3 clinical trials and will move into the role of vice chairman. He will help guide the companys clinical development plan and ensure KYZATREX and its differentiating safety and efficacy data is well known in the medical world.

It has been my great pleasure serving the company as CEO. I am very proud of the data we have generated, which we believe will position KYZATREX as the standard of care for patients suffering from hypogonadism globally, said Dr. Om Dhingra, vice chairman of Marius Pharmaceuticals.

If approved by the FDA, KYZATREX has the potential to become the new standard of care for treating patients with hypogonadism. Testosterone is a crucial hormone that is essential to sexual and reproductive health, but also has important functions in metabolic, inflammatory, cardiovascular and neurological health. In the U.S. there are at least six million symptomatic men suffering from hypogonadism, and over 100 million men globally. The resulting medical costs associated with men with untreated hypogonadism and related comorbidities are more than $25 billion in the U.S. alone. Current treatments on the market are dominated by therapies with unappealing administration methods, including auto-injections, in-office infusions and topical gels and creams that have a high transference risk. KYZATREX is an orally administered treatment that avoids the drawbacks that keep men from continuing treatment on available testosterone therapies.

About KYZATREX KYZATREX if approved, will represent a novel oral testosterone replacement therapy option for adult males indicated for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).

The ReTUNE study was a multi-center, 12-month study across the U.S. that studied the safety and efficacy of KYZATREX in hypogonadal subjects (total testosterone 281 ng/dL). Efficacy was determined by number of subjects in the normal, eugonadal range after 90 days of treatment, including dose titrations, while safety was monitored for a further 9 months while on a steady dose. In addition to testosterone parameters, the study collected Patient Reported Outcomes (PROs), which showed statistically significant results both from baseline and against its comparator. A pivotal six-month Phase 3 study was conducted, in which subjects were monitored using ABPM, now considered the standard BP assessment by the FDA and clinical experts. An improved dose regimen was also used in the pivotal six-month Phase 3 study. The results of the Phase 3 studies will be published in leading medical journals and presented at national conferences in 2021.

The FDA has conditionally accepted KYZATREX as the trade name for this investigational drug. The safety and efficacy have not been fully evaluated by any regulatory authority.

About Marius PharmaceuticalsMarius is a specialty pharmaceutical company focusing on treating conditions that are primarily associated with hypogonadism, commonly referred to as testosterone deficiency. The companys mission is to improve the functional lives of patients and reduce the risks of the downstream effects of endocrine imbalance by ensuring appropriate level of testosterone. For more information, please visit http://www.mariuspharma.com.

Media Contact: Emily Brice919-610-3319ebrice@fwv-us.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/f825d70b-874a-4cef-9160-429f83bbfc66

https://www.globenewswire.com/NewsRoom/AttachmentNg/ba2569ca-0922-4b49-8d68-49424b5e44d4

Himanshu H. Shah

Co-CEO and Chairman of the Board, Marius Pharmaceuticals

Shalin Shah

Co-CEO, Marius Pharmaceuticals

Read the rest here:
Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX...

Testosterone Gel Market

The latest report on Testosterone Gel Market provides an overall assessment of the world market Testosterone Gel by classifying it into terminal applications, types and regions. The report presents a comprehensive analysis of the competitive landscape and strategies that have positively influenced the market. Furthermore, the report provides an overview of current market dynamics by looking at different key segments based on product, types, applications, end-to-end industries and market scenario.

The Testosterone Gel market research report concentrates on the analysis of demand and supply at the regional and national global level. From a global perspective, the report presents Testosterone Gel markets per size, analysing historical data and future perspectives. The report focuses on a number of key areas, including North America, Europe, Asia-Pacific and the West.

2020 has been considered the base year and the report provides a market estimate for 2020-2029. The report looks at the world market for the Testosterone Gel (size, capacity, production and consumption) in key regions.

AbbVie, Upsher-Smith Laboratories, Endo Pharmaceuticals, Teva, Dr. Reddy\s Laboratories, Perrigo, Lupin, Acerus Pharmaceuticals

0.010.0162

Primary hypogonadismHypogonadotropic hypogonadismLate-onset hypogonadism

About Us:We, Regal Intelligence, aim to change the dynamics of market research backed by quality data. Our analysts validate data with exclusive qualitative and analytics driven intelligence. We meticulously plan our research process and execute in order to explore the potential market for getting insightful details. Our prime focus is to provide reliable data based on public surveys using data analytics techniques. If you have come here, you might be interested in highly reliable data driven market insights for your product/service,reach us here 24/7.

Mention your Queries here to Get a Call from Our Industry Expert @[emailprotected]

Contact Us:Regal Intelligence: http://www.regalintelligence.comPhone no: +1 231 930 2779 (U.S.) | +44 141 628 8787 (UK)

https://murphyshockeylaw.net/

Read more from the original source:
Testosterone Gel Market Analysis, Comperhensive Research: Sales, Consumption, Demand and Forecast 2020-2026 Murphy's Hockey Law - Murphy's Hockey Law

Testosterone Cypionate Injection Market

The latest report on Testosterone Cypionate Injection Market provides an overall assessment of the world market Testosterone Cypionate Injection by classifying it into terminal applications, types and regions. The report presents a comprehensive analysis of the competitive landscape and strategies that have positively influenced the market. Furthermore, the report provides an overview of current market dynamics by looking at different key segments based on product, types, applications, end-to-end industries and market scenario.

The Testosterone Cypionate Injection market research report concentrates on the analysis of demand and supply at the regional and national global level. From a global perspective, the report presents Testosterone Cypionate Injection markets per size, analysing historical data and future perspectives. The report focuses on a number of key areas, including North America, Europe, Asia-Pacific and the West.

2020 has been considered the base year and the report provides a market estimate for 2020-2029. The report looks at the world market for the Testosterone Cypionate Injection (size, capacity, production and consumption) in key regions.

Cipla, Paddock Laboratories, Pfizer, Hikma, Perrigo, Perrigo, Genesis Pharmaceuticals, Sun Pharma, Meditech Pharmaceutical

100mg/ml200mg/ml

HospitalClinicsRecovery Center

Chapter 1:- An overview of the market includes the definition, specifications and classification of the market Testosterone Cypionate Injection, characteristics, scope and applications.

Chapter 2:- Analysis of product costs and prices: structure of manufacturing costs, cost of raw materials and suppliers, manufacturing process, structure of the industrial chain.

Chapter 3:- Market demand and supply analysis which includes commercial production capacity and date, distribution of manufacturing plants, R&D status and technology source, analysis of raw material sources.

Chapter 4:- Forces that keep the marketplace going.

Chapter 5 and 6:- Regional Market Analysis that includes North America, Europe, China, Japan, Southeast Asia and India, Testosterone Cypionate Injection Market Analysis (by Type).

Chapter 7 and 8:- Industrial structure, Demand and Supply Gap Analysis.

Chapter 9:- Market Trend Analysis, Regional Market Trend, Market Trend according to Product Type.

Chapter 10:- Testosterone Cypionate Injection Turnover Channels, Distributors, Retailers, Dealers, Research Findings and Conclusion, Appendix along with Data Source.

About Us:We, Regal Intelligence, aim to change the dynamics of market research backed by quality data. Our analysts validate data with exclusive qualitative and analytics driven intelligence. We meticulously plan our research process and execute in order to explore the potential market for getting insightful details. Our prime focus is to provide reliable data based on public surveys using data analytics techniques. If you have come here, you might be interested in highly reliable data driven market insights for your product/service,reach us here 24/7.

Mention your Queries here to Get a Call from Our Industry Expert @[emailprotected]

Contact Us:Regal Intelligence: http://www.regalintelligence.comPhone no: +1 231 930 2779 (U.S.) | +44 141 628 8787 (UK)

https://murphyshockeylaw.net/

Excerpt from:
Testosterone Cypionate Injection Market Analysis, Exhaustive Size Was Estimated At Over USD Xx Billion In 2020 And Is Likely To Exceed USD Xx Billion...

Welcome back to Beauty Basics, a column dedicated to ending pervasive beauty myths (like whether or not pores open and close and if niacinamide is really all that!) once and for all. In this edition we're taking a look at the relationship between milk, acne, and skin inflammation.

Naturally, my mind went straight to my increased dairy intake, since the aphorism that "milk's bad for your skin" is as common as "drink water for good skin." (Been there, tried that). And interestingly, I wasnt completely wrong this time. We know that dairy, particularly skim milk, has been associated with skin inflammation and acne breakouts, says Dr. Joshua Zeichner, Associate Professor of Dermatology and Director of Cosmetic and Clinical Research at Mount Sinai Hospital. The thought is that skim milk contains a high sugar load as well as whey protein which activates messengers that stimulate our oil glands. This means more oil and inflammation, leading to acne breakouts.

Lets talk about whey protein real quick, since you might only know it as something you can buy in bulk for your smoothies. Whey proteins are mixtures of proteins isolated from whey, which is the liquid part of milk that separates when cheese is made, explains Skin Wellness Dermatologys Dr. Corey L. Hartman. From there, this protein can create a domino effect. Whey increases the production of Insulin-like Growth Factor 1 (IGF-1). Insulin increases the production of oil, which contributes to the development of acne. It also triggers androgen production, testosterone hormones that stimulate oil and cause acne, says Hartman. Dr. Joyce Imahiyerobo-Ip, CEO of Vibrant Dermatology and Skin Bar MD, also notes that cow milk contains caseinanother protein linked to IGF-1and high levels of progesterone, which is converted to an acne-stimulating hormone dihydroxytesterone in human sebaceous glands.

But wait, theres more. Daily Harvest nutritionist Amy Shapiro notes that while the hormone IGF-1 is found in our blood already, cows that are treated with Recombinant Bovine Growth Hormone (RBGH) tend to have higher IGF-1 levels, since RBGH stimulates milk production by stimulating the release of IGF-1. (Thats why certain dairy milks are advertised as RBGH-free.)

Swapping in non-dairy milk isnt a get-out-of-jail-free pass, either. Shapiro points out that while alt milks might not contain casein, whey protein, or hormones"which can help consumers avoid skin and digestive issues"they can be formulated with gums, emulsifiers, preservatives, carrageenans, and extra sugar. These can trigger gut and skin issues, too. When purchasing alt milks, I recommend reading ingredient labels first, she says. Look for clean, simple, whole-food-based ingredient lists.

So, remember how I said I love dairy milk? I still do, even though this is all a lot to take in. Dairy isnt all bad. Fermented dairy products, such as yogurt, help deliver probiotics to the body, says Zeichner. And that has a domino effect as well: Probiotics are bacteria that help restore a healthy microbiome. The microbiome is the collection of microorganisms, including bacteria, fungi, and viruses that live symbiotically on our bodies.

I switched from the occasional splash of skim milk just to see what would happen, and surprise, surprisemy involuntary sunburn went away. Although my nose is probably always going to look a little redder and jollier than Id like, my skin tone actually looks like the rest of my face now. Not too shabby for a skin care fix I can take with my coffee.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

Read the original:
Cow's Milk and Acne for Skin Myth - Skim Milk and Skin Inflammation - HarpersBAZAAR.com

Testosterone is also crucial for building muscle, says Blander. "It's an anabolic hormone," he notes, which means it stimulates muscle growth. Plus, when it's low, it's linked to a plethora of age-related concerns: According to one study, testosterone insufficiency in older men is associated with increased risk of death from heart disease. "There is also a strong correlation between levels of testosterone and age [itself]," Blander adds. "Every male, every year, loses between 1 and 2% of his testosterone levels during his life span. So if your testosterone stays higher, you are theoretically younger compared to your peers."

Admittedly, much of the research on low testosterone has been done on men (women have naturally lower levels of the hormone already, and doctors don't always have the same treatments for insufficient levels). But according to Blander, testosterone is importantfor both genderswhen it comes to its ratio with cortisol. (Again, cortisol can break down muscles.) "We need to find a way to make testosterone the highest possible, naturally, and then make the cortisol the lowest possible. Then you have a better way to build muscle."(Pro tip: A nutrient-dense diet rich in healthy fatslike a ketogenic dietcan help optimize testosterone levels.)

See the original post here:
The 3 Hormones This Longevity Expert Wants You To Focus On For Healthy Aging - mindbodygreen.com

Everyone has different amounts of facial hair. The fullness, growth pattern, and texture of a person's facial hair often differs from person to person. Compared to the hair on the scalp, beard hair tends to be thicker, coarser, and curlier.

"The biggest factor for beard growth is genetics. External hormones, like testosterone or other anabolic steroids, can sometimes make people grow thicker beards than they otherwise would," says Jay Vary, MD, PhD, associate professor of dermatology at the University of Washington.

It's important to maintain a healthy lifestyle because diet, stress levels, and exercise also influence beard growth. Here's what you need to know about growing a beard.

No, not everyone can grow a beard. "Beard growth is mainly genetically predisposed," says Anthony Rossi, MD, attending dermatologist at Memorial Sloan Kettering Cancer Center. "It is under genetic and hormonal control."

Therefore, facial hair growth will vary depending on your ethnicity, says Marisa Garshick, MD, FAAD, a dermatologist at MDCS Dermatology.

In general, for those with testes, beard growth starts during puberty as testosterone levels increase. Testosterone is key for beard growth because its byproduct, dihydrotestosterone (DHT), triggers hair follicles to grow longer and thicker hairs. For transgender men, the growth of facial hair typically begins a year or more after starting their testosterone intake.

Though beard growth depends heavily on your genetics, there are some things you can do to improve the facial hair you do have and encourage it to grow.

Here are six tips from the American Academy of Dermatology Association for growing a healthy beard:

Moreover, it's important to keep the skin in the beard area as healthy as possible to avoid acne and dandruff.

It varies among different people as some grow fuller beards faster than others, says Rossi.

"Beard hair can grow at a rate of half an inch per month. It is possible to begin to grow a beard in two weeks as it is thought that facial hair grows faster than scalp hair, but it can take up to two to four months to grow a full beard," says Garshick.

According to Vary, most beards continue to grow thicker as people age into their 20s and 30s. However, if you've tried and haven't developed a thick, full beard by age 30, then it's less likely to see a big difference because that's when testosterone levels start to decrease with age, says Garshick.

You may not be able to grow a beard instantaneously, but certain practices can help stimulate hair growth, such as:

"Depending on how much it bothers you, there is such a thing as a beard transplant to actually take hairs from the back of your scalp and place them in your beard area," says Garshick.

You don't have to undergo this procedure unless you find your facial hair to be a major cosmetic concern.

One of the biggest factors for beard growth is genetics, but testosterone levels, diet, exercise, and stress levels can also influence it. Beard hair grows about half an inch per month, and it will take you about two to four months to grow a full beard from having a clean-shaven face.

Shaving generally doesn't make hair grow thicker, but you can encourage beard growth by maintaining a healthy lifestyle. Proper grooming, such as cleansing and moisturizing the beard area, is important to have a healthy-looking beard.

"If someone is trying to grow a beard, patience and genetics need to be on their side," says Vary. "Some people were born to grow thick beards and others were born to grow thinner beards or none at all."

See the article here:
6 dermatologist-approved tips to grow a healthy, full beard - Insider - INSIDER

The Global Androgen Replacement Therapy Market report provides a holistic evaluation of the market for the forecast period (20192025). The report comprises various segments as well as an analysis of the trends and factors that are playing a substantial role in the market. These factors; the market dynamics involve the drivers, restraints, opportunities and challenges through which the impact of these factors in the market are outlined. The drivers and restraints are intrinsic factors whereas opportunities and challenges are extrinsic factors of the market. The Global Androgen Replacement Therapy Market study provides an outlook on the development of the market in terms of revenue throughout the prognosis period.

In order to present an executive-level model of the market and its future perspectives, the Androgen Replacement Therapy Market report presents a clear segmentation based on different parameters. The factors that affect these segments are also discussed in detail in the report.

Androgen replacement therapy (ART), often referred to as testosterone replacement therapy (TRT), is a form of hormone therapy, in which androgens, often testosterone, are replaced. ART is often prescribed to counter the effects of male hypogonadism. It typically involves the administration of testosterone through injections, skin creams, patches, gels, or subcutaneous pellets. Testosterone replacement therapy is a promising technology for improving symptoms of hypogonadism and to raise the testosterone level. Furthermore, benefits related to application of testosterone replacement therapy include an increase in muscle tissue, overall surge in energy, and significant decrease in depression symptoms.

Major Players included in this report are as follows AbbVie, Inc., Allergan Plc, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International Plc, Mylan N.V., Novartis International AG, Pfizer, Inc., Clarus Therapeutics, Ferring Holding SA, Perrigo Company Plc, Acerus Pharmaceuticals Corporation, Upsher-Smith Laboratories, LLC, Dr. Reddys Laboratories, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., and Par Pharmaceutical.

Get PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/3787

Androgen Replacement Therapy Market: Regional analysis includes:

The study will also feature the key companies operating in the industry, their product/business portfolio, market share, financial status, regional share, segment revenue, SWOT analysis, key strategies including mergers & acquisitions, product developments, joint ventures & partnerships an expansions among others, and their latest news as well. The study will also provide a list of emerging players in the Androgen Replacement Therapy Market.

Androgen Replacement Therapy Market scope

A basic summary of the competitive landscape A detailed breakdown of the regional expanse A short overview of the segmentation

Furthermore, this study will help our clients solve the following issues:

Cyclical dynamics We foresee dynamics of industries by using core analytical and unconventional market research approaches. Our clients use insights provided by us to maneuver themselves through market uncertainties and disruptions.

Identifying key cannibalizes Strong substitute of a product or service is the most prominent threat. Our clients can identify key cannibalizes of a market, by procuring our research. This helps them in aligning their new product development/launch strategies in advance.

Spotting emerging trends Our Ecosystem offering helps the client to spot upcoming hot market trends. We also track possible impact and disruptions which a market would witness by a particular emerging trend. Our proactive analysis helps clients to have an early mover advantage.

Interrelated opportunities This report will allow clients to make decisions based on data, thereby increasing the chances that the strategies will perform better if not best in the real world.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/3787

Some of the Major Highlights of TOC covers:

Androgen Replacement Therapy Regional Market Analysis

Androgen Replacement Therapy Production by Regions Global Androgen Replacement Therapy Production by Regions Global Androgen Replacement Therapy Revenue by Regions Androgen Replacement Therapy Consumption by Regions

Androgen Replacement Therapy Segment Market Analysis (by Type)

Global Androgen Replacement Therapy Production by Type Global Androgen Replacement Therapy Revenue by Type Androgen Replacement Therapy Price by Type

Androgen Replacement Therapy Segment Market Analysis (by Application)

Global Androgen Replacement Therapy Consumption by Application Global Androgen Replacement Therapy Consumption Market Share by Application (2014-2019)

Androgen Replacement Therapy Major Manufacturers Analysis

Androgen Replacement Therapy Production Sites and Area Served Product Introduction, Application and Specification Androgen Replacement Therapy Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)Main Business and Markets Served

Key questions answered in the report:

LIMITED TIME OFFER Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Apply Promo Code CMIFIRST1000 And Get Instant Discount Of USD 1000

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/3787

Key Benefits

Major countries in each region are mapped according to individual market revenue. Comprehensive analysis of factors that drive and restrict market growth is provided. The report includes an in-depth analysis of current research and clinical developments within the market. Key players and their key developments in recent years are listed.And More.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Tel: +1-206-701-6702Email: sales@coherentmarketinsights.com

Go here to see the original:
Androgen Replacement Therapy Market to Witness Robust Expansion throughout the Forecast Period 2017-2026 | AbbVie, Inc., Allergan Plc, Bayer AG, Endo...

Page 20«..10..19202122..3040..»

Home » Testosterone » Page 20